Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Long-Term Debt Repayments (2022 - 2025)

Icu Medical (ICUI) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments rose 135.29% year-over-year to $30.0 million, compared with a TTM value of $302.8 million through Dec 2025, up 493.63%, and an annual FY2025 reading of $302.8 million, up 493.63% over the prior year.
  • Long-Term Debt Repayments was $30.0 million for Q4 2025 at Icu Medical, up from $25.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $200.0 million in Q2 2025 and bottomed at $2.1 million in Q2 2022.
  • Average Long-Term Debt Repayments over 4 years is $25.4 million, with a median of $12.8 million recorded in 2024.
  • The sharpest move saw Long-Term Debt Repayments crashed 53.91% in 2023, then skyrocketed 1468.63% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $2.1 million in 2022, then surged by 250.02% to $7.4 million in 2023, then skyrocketed by 71.42% to $12.8 million in 2024, then soared by 135.29% to $30.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for ICUI at $30.0 million in Q4 2025, $25.0 million in Q3 2025, and $200.0 million in Q2 2025.